135 related articles for article (PubMed ID: 36990249)
21. [New perspectives for radiosensitization in pancreatic carcinoma: a review of mechanisms involved in pancreatic tumorigenesis].
Huguet F; Fernet M; Monnier L; Touboul E; Favaudon V
Cancer Radiother; 2011 Aug; 15(5):365-75. PubMed ID: 21664851
[TBL] [Abstract][Full Text] [Related]
22. Comparative genomic analysis of head and body/tail of pancreatic ductal adenocarcinoma at early and late stages.
Zhang X; Feng S; Wang Q; Huang H; Chen R; Xie Q; Zhang W; Wang A; Zhang S; Wang L; Yao M; Ling Q
J Cell Mol Med; 2021 Feb; 25(3):1750-1758. PubMed ID: 33452856
[TBL] [Abstract][Full Text] [Related]
23. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
Ruess DA; Görgülü K; Wörmann SM; Algül H
Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
[TBL] [Abstract][Full Text] [Related]
24. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
Blasco MT; Navas C; Martín-Serrano G; Graña-Castro O; Lechuga CG; Martín-Díaz L; Djurec M; Li J; Morales-Cacho L; Esteban-Burgos L; Perales-Patón J; Bousquet-Mur E; Castellano E; Jacob HKC; Cabras L; Musteanu M; Drosten M; Ortega S; Mulero F; Sainz B; Dusetti N; Iovanna J; Sánchez-Bueno F; Hidalgo M; Khiabanian H; Rabadán R; Al-Shahrour F; Guerra C; Barbacid M
Cancer Cell; 2019 Apr; 35(4):573-587.e6. PubMed ID: 30975481
[TBL] [Abstract][Full Text] [Related]
25. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
26. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
Calabretta S; Bielli P; Passacantilli I; Pilozzi E; Fendrich V; Capurso G; Fave GD; Sette C
Oncogene; 2016 Apr; 35(16):2031-9. PubMed ID: 26234680
[TBL] [Abstract][Full Text] [Related]
27. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer.
Lee HS; Kim E; Lee J; Park SJ; Hwang HK; Park CH; Jo SY; Kang CM; Hong SM; Kang H; Jo JH; Cho IR; Chung MJ; Park JY; Park SW; Song SY; Han JM; Kim S; Bang S
EBioMedicine; 2021 Mar; 65():103218. PubMed ID: 33639403
[TBL] [Abstract][Full Text] [Related]
28. NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma.
Ramakrishnan G; Parajuli P; Singh P; Friend C; Hurwitz E; Prunier C; Razzaque MS; Xu K; Atfi A
Cell Rep; 2022 Nov; 41(6):111623. PubMed ID: 36351408
[TBL] [Abstract][Full Text] [Related]
29. Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer.
Tasaki Y; Suzuki M; Katsushima K; Shinjo K; Iijima K; Murofushi Y; Naiki-Ito A; Hayashi K; Qiu C; Takahashi A; Tanaka Y; Kawaguchi T; Sugawara M; Kataoka T; Naito M; Miyata K; Kataoka K; Noda T; Gao W; Kataoka H; Takahashi S; Kimura K; Kondo Y
Cancer Res; 2021 Apr; 81(7):1654-1666. PubMed ID: 33648930
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
[TBL] [Abstract][Full Text] [Related]
31. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
[TBL] [Abstract][Full Text] [Related]
32. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
33. ABCC3 is a novel target for the treatment of pancreatic cancer.
Adamska A; Ferro R; Lattanzio R; Capone E; Domenichini A; Damiani V; Chiorino G; Akkaya BG; Linton KJ; De Laurenzi V; Sala G; Falasca M
Adv Biol Regul; 2019 Aug; 73():100634. PubMed ID: 31053501
[TBL] [Abstract][Full Text] [Related]
34. Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma.
Satoh K; Hamada S; Shimosegawa T
J Gastroenterol; 2015 Feb; 50(2):140-6. PubMed ID: 25216997
[TBL] [Abstract][Full Text] [Related]
35. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
36. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
38. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
[TBL] [Abstract][Full Text] [Related]
39. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
[TBL] [Abstract][Full Text] [Related]
40. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.
Ng CF; Glaspy J; Placencio-Hickok VR; Thomassian S; Gong J; Osipov A; Hendifar AE; Moshayedi N
J Natl Compr Canc Netw; 2022 Oct; 20(10):1076-1079. PubMed ID: 36240849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]